Scribe Therapeutics Reports Q2 GAAP EPS and Revenue Results
Scribe Therapeutics Inc. (NASDAQ:SCTX) reported a second-quarter GAAP earnings per share (EPS) loss of -$2.62, which beat expectations by $1.15. However, the company's revenue came in at $1.92 million, missing estimates by $1.19 million and declining 60.8% year-over-year. Despite the drop in revenue, Scribe Therapeutics maintained a strong cash position as of June 30, with $43.0 million in cash, cash equivalents, and marketable securities. The company also announced approximately $140.6 million in net proceeds from fundraising activities, which could support ongoing operations or future growth initiatives. The mixed financial performance highlights the challenges faced by biotech firms during early-stage development while demonstrating resilience through strong liquidity.
Tickers: $SCTX
Topics: Earnings Financial Performance